XNYS · Healthcare · Diagnostics & Research
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | 2.76 | 2.90 | +5.07% | $4.15B | ✅ Beat | +1.28% | -0.77% | — |
| 2026-02-05 | Q4 2025 | 3.29 | 3.42 | +3.95% | $4.36B | ✅ Beat | +0.23% | -6.69% | -3.58% |
| 2025-10-28 |
| Q3 2025 |
| 2.86 |
| 3.00 |
| +4.90% |
| $4.10B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-22 | Q2 2025 | 2.66 | 2.81 | +5.64% | $4.02B | ✅ Beat | +4.43% | +3.83% | -1.06% |
| 2025-05-06 | Q1 2025 | 2.63 | 2.70 | +2.66% | $3.83B | ✅ Beat | +4.86% | +3.06% | +0.80% |
| 2025-02-06 | Q4 2024 | 3.11 | 3.12 | +0.32% | $3.96B | ✅ Beat | -0.87% | -6.63% | -10.09% |
| 2024-10-31 | Q3 2024 | 2.81 | 2.84 | +1.07% | $3.90B | ✅ Beat | +1.62% | +5.76% | -1.96% |
| 2024-07-22 | Q2 2024 | 2.56 | 2.64 | +3.12% | $3.81B | ✅ Beat | -2.63% | -3.25% | +0.72% |
Showing last 8 quarters.